Status:
COMPLETED
Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
Lawson Health Research Institute Internal Review Fund
University of Western Ontario, Canada
Conditions:
Prostate Cancer
Bone Loss
Eligibility:
MALE
40+ years
Brief Summary
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is ex...
Eligibility Criteria
Inclusion
- Men
- Age of 40 years or greater
- Diagnosis of advanced prostate cancer (ie: prostate-specific antigen \[PSA\] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone \[LHRH\] therapy)
- Willing and able to consent
Exclusion
- Metastatic disease to bone
- Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
- Renal failure (serum creatinine \> 200 umol/L)
- Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
- Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
- Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
- Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
- Parathyroid disease
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00199537
Start Date
February 1 2005
End Date
February 1 2008
Last Update
July 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London
London, Ontario, Canada, N6A 4V2